NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.3 Antimetabolites > Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts - NICE TAG TA399

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts - NICE TAG TA399

1.1 Azacitidine is not recommended, within its marketing authorisation, for treating acute myeloid leukaemia with more than 30% bone marrow blasts in people of 65 years or older who are not eligible for haematopoietic stem cell transplant.

1.2 This guidance is not intended to affect the position of patients whose treatment with azacitidine was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta399

Site by Devopa
© Copyright 2019 NHS. All rights reserved.